

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated October 6, 2025 (the “**Prospectus**”) of Xuanzhu Biopharmaceutical Co., Ltd. (軒竹生物科技股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged or otherwise transferred within the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. The securities are being offered and sold outside the United States in offshore transactions in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

Potential investors of the Offer Shares should note that the Joint Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – The Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. on the Listing Date.



Xuanzhu Biopharmaceutical Co., Ltd.

軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares : 67,333,500 H Shares
in the Global Offering
Number of Hong Kong Offer Shares : 6,733,500 H Shares
Number of International Offer Shares : 60,600,000 H Shares (including
3,366,500 Reserved Shares under the
Preferential Offering)
Offer Price : HK\$11.60 per H Share, plus brokerage of
1.0 %, SFC transaction levy of 0.0027 %, AFRC transaction levy of 0.00015 % and
Stock Exchange trading fee of 0.00565 %
Nominal Value : RMB1.00 per H Share
Stock Code : 2575

Sole Sponsor and Sponsor-Overall Coordinator



*Joint Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and
Joint Lead Managers*



XUANZHU BIOPHARMACEUTICAL CO., LTD.
軒竹生物科技股份有限公司
ANNOUNCEMENT OF ALLOTMENT RESULTS

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated October 6, 2025 (the “**Prospectus**”) issued by Xuanzhu Biopharmaceutical Co., Ltd. (軒竹生物科技股份有限公司) (the “**Company**”).*

Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company Information

Stock code	2575
Stock short name	XUANZHUBIO-B
Dealings commencement date	October 15, 2025*

* see note at the end of the announcement

Price Information

Offer Price	HK\$11.60
--------------------	-----------

Offer Shares and Share Capital	
Number of Offer Shares	67,333,500
Number of Offer Shares in Hong Kong Public Offering	6,733,500
Number of Offer Shares in International Offering (excluding Reserved Shares under the Preferential Offering)	57,233,500
Final no. of Reserved Shares in the Preferential Offering	3,366,500
Number of issued Shares upon Listing	517,947,790
Over-allocation	
Number of Offer Shares over-allocated	–
Proceeds	
Gross proceeds ^(Note)	HK\$781.1 million
Less: Estimated listing expenses payable based on Offer Price	HK\$(80.1) million
Net proceeds	HK\$701.0 million
<i>Note: Gross proceeds refer to the amount which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.</i>	

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

Number of valid applications	376,021
Number of successful applications	13,467
Subscription level	4,908.33 times
Claw-back triggered	N/A
Number of Offer Shares initially available under the Hong Kong Public Offering	6,733,500
Final number of Offer Shares under the Hong Kong Public Offering	6,733,500
Number of Offer Shares reallocated from International Offering to Hong Kong Public Offering	0
% of final number of Offer Shares under the Hong Kong Public Offering to the Global Offering	10.00%

Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to www.eipo.com.hk/eIPOAllotment to perform a search by identification number or www.eipo.com.hk/eIPOAllotment for the full list of allottees.

INTERNATIONAL OFFERING

Number of places	105
Subscription Level (excluding Reserved Shares under the Preferential Offering)	10.15 times
Number of Offer Shares initially available under the International Offering (excluding Reserved Shares under the Preferential Offering)	57,233,500
Final number of Offer Shares under the International Offering (excluding Reserved Shares under the Preferential Offering)	57,233,500
Final number of Reserved Shares in Preferential Offering	3,366,500
Final number of Offer Shares under the International Offering (including Reserved Shares under the Preferential Offering)	60,600,000
% of Offer Shares under the International Offering to the Global Offering	90.00%

The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, substantial Shareholders, Controlling Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, substantial Shareholders, Controlling Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

PREFERENTIAL OFFERING

Number of valid applications	114
Subscription level	72.49 times
Final number of Shares allotted	3,366,500
Reserved Shares available under International Offering	3,366,500

The placees in the International Offering include the following:

Cornerstone Investor

<i>Investor</i> ^(Note)	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued Shares after the Global Offering</i>	<i>Existing Shareholders or their close associates</i>
Beijing Denov Ruilang Phase XV Equity Investment Fund Center (Limited Partnership) (北京德諾瑞朗十五期股權投資基金中心(有限合夥)) (“Denov Ruilang Phase XV”)	6,603,000	9.81%	4.11%	1.27%	No
Total	6,603,000	9.81%	4.11%	1.27%	
<i>Note: For further details of the Cornerstone Investor, please refer to the section headed “Cornerstone Investor” in the Prospectus.</i>					

Allottee with consent obtained

<i>Investor</i> ^(Note)	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares</i>	<i>% of total issued H Shares after the Global Offering</i>	<i>% of total issued Shares after the Global Offering</i>	<i>Relationship</i>
<i>Allottee with consent under paragraph 1C(1) of the Appendix F1 to the Listing Rules (the “Placing Guidelines”) and Chapter 4.15 of the Guide for New Listing Applicants in relation to allocation to a connected client</i> ^{Note}					
Bosera Asset Management (International) Co., Ltd. (“Bosera AM”)	20,000	0.03%	0.01%	0.004%	Connected client
<i>Note: For details of the consent under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Guide for New Listing Applicants in relation to the allocation to a connected client, please refer to the section headed “Others/Additional Information – Placing to a Connected Client with a Prior Consent under Paragraph 1C(1) of the Placing Guidelines” in this announcement.</i>					

LOCK-UP UNDERTAKINGS

Controlling Shareholders

<i>Name</i>	<i>Number of Unlisted Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings</i> ^{Note}
Xuanzhu (HK) Biopharmaceutical Limited/ 軒竹(香港)醫藥科技有限公司	215,294,494	–	0.00%	41.57%	October 14, 2026
Hainan Sihuan Pharmaceutical Co., Ltd./ 海南四環醫藥有限公司	39,156,920	–	0.00%	7.56%	October 14, 2026
Sub-total	254,451,414	–	0.00%	49.13%	
<i>Note: The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. The required lock-up for the Controlling Shareholders ends on October 14, 2026, being 12 months following the Listing Date.</i>					

Existing Shareholders

<i>Name</i>	<i>Number of Unlisted Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings ^{Note}</i>
Xu Yanjun/徐艷君	–	4,714,400	2.93%	0.91%	October 14, 2026
Li Jia Kui/李嘉達	–	3,020,800	1.88%	0.58%	October 14, 2026
Shih Cheng-Kon/史澂空	–	1,700,000	1.06%	0.33%	October 14, 2026
Tianjin Zhenxuan Pharmaceutical Technology Partnership (Limited Partnership)/天津振軒醫藥科技合夥企業(有限合夥)	–	36,049,144	22.43%	6.96%	October 14, 2026
Beihai Baimei'en Investment Partnership (Limited Partnership)/北海百美恩投資合夥企業(有限合夥)	–	13,039,600	8.11%	2.52%	October 14, 2026
Beihai Jixin Xuanzhu Investment Partnership (Limited Partnership)/北海吉鑫軒竹投資合夥企業(有限合夥)	–	8,466,510	5.27%	1.63%	October 14, 2026
Beihai Keya Xuanzhu Investment Partnership (Limited Partnership)/北海科雅軒竹投資合夥企業(有限合夥)	–	3,849,190	2.40%	0.74%	October 14, 2026
Tianjin Hongzekang Pharmaceutical Technology Partnership (Limited Partnership)/天津泓澤康醫藥科技合夥企業(有限合夥)	–	2,969,200	1.85%	0.57%	October 14, 2026

<i>Name</i>	<i>Number of Unlisted Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings^{Note}</i>
Tianjin Xuansheng Pharmaceutical Technology Partnership (Limited Partnership)/天津軒升醫藥科技合夥企業(有限合夥)	–	2,485,600	1.55%	0.48%	October 14, 2026
Tianjin Hongteng Pharmaceutical Technology Partnership (Limited Partnership)/天津泓騰醫藥科技合夥企業(有限合夥)	–	1,919,600	1.19%	0.37%	October 14, 2026
Tianjin Pusheng Pharmaceutical Technology Partnership (Limited Partnership)/天津普晟醫藥科技合夥企業(有限合夥)	–	999,200	0.62%	0.19%	October 14, 2026
Tianjin Guoding Pharmaceutical Technology Partnership (Limited Partnership)/天津國鼎醫藥科技合夥企業(有限合夥)	–	958,000	0.60%	0.18%	October 14, 2026
Tianjin Huize Pharmaceutical Technology Partnership (Limited Partnership)/天津匯澤醫藥科技合夥企業(有限合夥)	–	655,600	0.41%	0.13%	October 14, 2026
Subtotal	–	80,826,844	50.30%	15.61%	
<i>Note: The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. The required lock-up for the Existing Shareholders ends on October 14, 2026, being 12 months following the Listing Date.</i>					

Pre-IPO Investors

<i>Name</i>	<i>Number of Unlisted Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings ^{Note}</i>
Metropolitan Industrial Investment Fund/京津冀產業協同發展投資基金(有限合夥)	70,032,855	–	0.00%	13.52%	October 14, 2026
Future Industry Investment Fund II/先進製造產業投資基金二期(有限合夥)	23,344,465	–	0.00%	4.51%	October 14, 2026
Shijiazhuang Keshuo Investment Centre (Limited Partnership)/石家莊科碩投資中心(有限合夥)	8,170,500	3,501,643	2.18%	2.25%	October 14, 2026
Beijing Tonghe Yinxing Innovative Asset Management Centre (Limited Partnership)/北京同合銀杏創新資產管理中心(有限合夥)	–	7,353,450	4.58%	1.42%	October 14, 2026
Beijing SL Pharmaceutical Co., Ltd./北京雙鷺藥業股份有限公司	1,246,560	534,240	0.33%	0.34%	October 14, 2026
Shanghai Yunxin Venture Capital Partnership (Limited Partnership)/上海雲鉉創業投資合夥企業(有限合夥)	–	1,152,319	0.72%	0.22%	October 14, 2026
Subtotal	102,794,380	12,541,652	7.80%	22.27%	
<i>Note: The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. The required lock-up for the Pre-IPO Investors ends on October 14, 2026, being 12 months following the Listing Date.</i>					

Cornerstone Investor

<i>Name</i>	<i>Number of Unlisted Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of total issued H Shares after the Global Offering subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings^{Note}</i>
Beijing Denov Ruilang Phase XV Equity Investment Fund Center (Limited Partnership)/ 北京德諾瑞朗十五期股權投資基金中心(有限合夥)	–	6,603,000	4.11%	1.27%	April 14, 2026
Subtotal	–	6,603,000	4.11%	1.27%	
<i>Note: The expiry date of the lock-up period shown in the table above is pursuant to the Cornerstone Investment Agreement. The required lock-up for the Cornerstone Investor ends on April 14, 2026, being 6 months following the Listing Date.</i>					

PLACEE CONCENTRATION ANALYSIS

Placees ⁽¹⁾	Number of H Shares allotted ⁽²⁾	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing ⁽²⁾	% of total issued Share capital upon Listing
Top 1	6,603,000	10.90%	9.81%	6,603,000	1.27%
Top 5	19,953,000	32.93%	29.63%	19,953,000	3.85%
Top 10	29,621,000	48.88%	43.99%	29,621,000	5.72%
Top 25	52,762,000	87.07%	78.36%	52,762,000	10.19%

Notes:

1. *Ranking of placees is based on the number of H Shares allotted to the placees.*
2. *Excluding Reserved Shares allotted under the Preferential Offering (if any).*

H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders ⁽¹⁾	Number of H Shares allotted ⁽²⁾	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing ⁽²⁾	% of total issued H Share capital upon Listing	Number of Shares held upon Listing ⁽²⁾	% of total issued Share capital upon Listing
Top 1	0	0.00%	0.00%	36,049,144	22.43%	36,049,144	6.96%
Top 5	6,603,000	10.90%	9.81%	75,360,894	46.89%	75,360,894	14.55%
Top 10	14,603,000	24.10%	21.69%	94,597,737	58.87%	102,768,237	19.84%
Top 25	36,695,000	60.55%	54.50%	125,764,137	78.26%	133,934,637	25.86%

Notes:

1. *Ranking of H Shareholders is based on the number of H Shares held by the H Shareholder upon Listing.*
2. *Excluding Reserved Shares allotted under the Preferential Offering (if any).*

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders ⁽¹⁾	Number of H Shares allotted ⁽²⁾	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of H Shares held upon Listing ⁽²⁾	Number of Shares held upon Listing ⁽²⁾	% of total issued Share capital upon Listing
Top 1	0	0.00%	0.00%	0	254,451,414	49.13%
Top 5	0	0.00%	0.00%	61,404,444	409,233,178	79.01%
Top 10	11,603,000	19.15%	17.23%	88,576,937	444,576,171	85.83%
Top 25	33,276,000	54.91%	49.42%	121,179,377	478,425,171	92.37%

Notes:

1. Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.
2. Excluding Reserved Shares allotted under the Preferential Offering (if any).

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, a total of 376,021 valid applications made by the public will be conditionally allocated on the basis set out below:

Number of H Shares applied for	Number of valid applications	Basis of allotment/ballot	Approximate percentage allotted of the total number of H Shares applied for
POOL A			
500	190,432	1,895 out of 190,432 to receive 500 H Shares	1.00%
1,000	21,196	211 out of 21,196 to receive 500 H Shares	0.50%
1,500	9,928	99 out of 9,928 to receive 500 H Shares	0.33%
2,000	9,417	94 out of 9,417 to receive 500 H Shares	0.25%
2,500	6,805	68 out of 6,805 to receive 500 H Shares	0.20%
3,000	4,654	47 out of 4,654 to receive 500 H Shares	0.17%
3,500	2,586	27 out of 2,586 to receive 500 H Shares	0.15%
4,000	10,024	105 out of 10,024 to receive 500 H Shares	0.13%
4,500	1,953	21 out of 1,953 to receive 500 H Shares	0.12%
5,000	10,839	117 out of 10,839 to receive 500 H Shares	0.11%
6,000	3,094	36 out of 3,094 to receive 500 H Shares	0.10%
7,000	2,176	26 out of 2,176 to receive 500 H Shares	0.09%
8,000	4,200	51 out of 4,200 to receive 500 H Shares	0.08%
9,000	3,958	49 out of 3,958 to receive 500 H Shares	0.07%
10,000	9,105	113 out of 9,105 to receive 500 H Shares	0.06%
15,000	5,271	74 out of 5,271 to receive 500 H Shares	0.05%
20,000	4,434	63 out of 4,434 to receive 500 H Shares	0.04%

Approximate
percentage
allotted of the
total number
of H Shares
applied for

Number of H
Shares applied
for

Number of valid
applications

Basis of allotment/ballot

POOL A

25,000	3,397	49 out of 3,397 to receive 500 H Shares	0.03%
30,000	2,885	44 out of 2,885 to receive 500 H Shares	0.03%
35,000	2,041	36 out of 2,041 to receive 500 H Shares	0.03%
40,000	2,396	48 out of 2,396 to receive 500 H Shares	0.03%
45,000	1,898	43 out of 1,898 to receive 500 H Shares	0.03%
50,000	4,356	110 out of 4,356 to receive 500 H Shares	0.03%
60,000	2,846	86 out of 2,846 to receive 500 H Shares	0.03%
70,000	2,241	79 out of 2,241 to receive 500 H Shares	0.03%
80,000	2,283	92 out of 2,283 to receive 500 H Shares	0.03%
90,000	1,904	86 out of 1,904 to receive 500 H Shares	0.03%
100,000	10,688	540 out of 10,688 to receive 500 H Shares	0.03%
200,000	6,606	662 out of 6,606 to receive 500 H Shares	0.03%
300,000	4,486	603 out of 4,486 to receive 500 H Shares	0.02%
400,000	8,406	1,160 out of 8,406 to receive 500 H Shares	0.02%

356,505 Total number of Pool A successful applicants: 6,734

POOL B

500,000	5,341	806 out of 5,341 to receive 500 H Shares	0.02%
600,000	1,871	340 out of 1,871 to receive 500 H Shares	0.02%
700,000	1,285	271 out of 1,285 to receive 500 H Shares	0.02%
800,000	1,181	285 out of 1,181 to receive 500 H Shares	0.02%
900,000	825	224 out of 825 to receive 500 H Shares	0.02%
1,000,000	2,802	846 out of 2,802 to receive 500 H Shares	0.02%
1,500,000	1,864	841 out of 1,864 to receive 500 H Shares	0.02%
2,000,000	1,931	1,160 out of 1,931 to receive 500 H Shares	0.02%
3,366,500	2,416	1,960 out of 2,416 to receive 500 H Shares	0.01%

19,516 Total number of Pool B successful applicants: 6,733

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

BASIS OF ALLOCATION UNDER THE PREFERENTIAL OFFERING

The final number of Reserved Shares allocated to Qualifying Sihuan Shareholders in the Preferential Offering is 3,366,500 Reserved Shares, representing approximately 5% of the Offer Shares initially available under the Global Offering. Such 3,366,500 Reserved Shares have been allocated to a total of 108 Qualifying Sihuan Shareholders. Among the Reserved Shares allocated, 9 valid applications in respect of a total of 2,197,214 Reserved Shares will be allocated to Qualifying Sihuan Shareholders as their Assured Entitlement and 105 valid applications in respect of a total of 1,169,286 Reserved Shares will be allocated to Qualifying Sihuan Shareholders under their valid applications for excess Reserved Shares.

No preferential treatment was given to any of the Qualifying Sihuan Shareholders in the allocation of the Reserved Shares applied for by them under the Preferential Offering and such allocation of Reserved Shares under the Preferential Offering was made in accordance with the allocation basis disclosed in the section headed “Structure of the Global Offering – The Preferential Offering – Basis of Allocation for Applications for the Reserved Shares” in the Prospectus. Valid applications made by Qualifying Sihuan Shareholders for excess Reserved Shares on BLUE Form eIPO will be conditionally allotted on the basis set out below:

Number of H Shares applied for	Number of Applications	Total number of excess Reserved Shares applied for	Basis of allotment/ballot	Total number of Reserved Shares allotted	Approximate percentage of allocation based on the the total number of excess Reserved Shares applied for in this category
5 to 500	13	3,529	Allot Excess Reserved Shares applied for in full	3,529	100.00%
1,000	8	8,000	50% of the Excess Reserved Shares applied for	4,000	50.00%
1,001 to 1,500	2	2,997	40% of the Excess Reserved Shares applied for	1,199	40.00%
2,000	6	12,000	30% of the Excess Reserved Shares applied for	3,600	30.00%
4,000	1	4,000	20% of the Excess Reserved Shares applied for	800	20.00%
5,000	7	35,000	18% of the Excess Reserved Shares applied for	6,300	18.00%
7,000	2	14,000	14% of the Excess Reserved Shares applied for	1,960	14.00%
10,000 to 15,000	7	80,000	10% of the Excess Reserved Shares applied for	8,000	10.00%
25,000 to 45,000	4	135,000	6% of the Excess Reserved Shares applied for	8,100	6.00%
60,000 to 900,000	53	18,338,000	5% of the Excess Reserved Shares applied for	916,900	5.00%
2,000,000	1	2,000,000	3% of the Excess Reserved Shares applied for	60,000	3.00%
221,198,756	1	221,198,756	Approximately 0.07% of the Excess Reserved Shares applied for (HKSCC Nominees Limited apply on behalf of the applicants who apply in CCASS indirectly through a broker/custodian)	154,898	0.07%
	105	241,831,282		1,169,286	

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the H Shares.

The Directors confirm that, to the best of their knowledge, no rebate has been, directly or indirectly, provided by the Company, Directors or syndicate members to any placees or the public (as the case may be) and the consideration paid by them for each Offer Share subscribed for or purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

OTHERS/ADDITIONAL INFORMATION

Placing to a connected client with a prior consent under paragraph 1C(1) of the Placing Guidelines

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 1C(1) of the Placing Guidelines to permit certain Offer Shares to be placed to a connected client of its connected distributor under the International Offering. The allocation of Offer Shares to such connected client is in compliance with all the conditions under the consent granted by the Stock Exchange.

Details of the placement to the connected client are set out below.

No.	Connected Client	Connected Distributor	Relationship with the Connected Distributor	Whether the connected client will hold beneficial interests of Offer Shares on a non-discretionary or discretionary basis for independent third parties	Number of Offer Shares to be allocated to the connected client	Appropriate percentage of total number of Offer Shares	Approximate percentage of total issued share capital immediately following the completion of Global Offering
1.	Bosera AM ^(Note)	CMB International Capital Limited (“CMBI”), CMB International Securities Limited (“CMBI Securities”), and CMB International Global Markets Limited (“CMBI Global Markets”, together with CMBI and CMBI Securities, the “CMBI Connected Distributors”)	Bosera AM is a member of the same group with CMBI, CMBI Securities and CMBI Global Markets.	Discretionary basis	20,000	0.03%	0.004%
<i>Note:</i> Bosera AM will hold the Offer Shares in its capacity as a discretionary fund manager managing assets on behalf of its underlying clients. To the best knowledge of Bosera AM after due enquiry, each underlying clients of Bosera AM is an independent third party of Bosera AM, the CMBI Connected Distributors and the companies which are members of the same group of the CMBI Connected Distributors.							

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated October 6, 2025 issued by Xuanzhu Biopharmaceutical Co., Ltd. (軒竹生物科技股份有限公司) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.

** Potential investors of the Offer Shares should note that the Joint Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – The Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Wednesday, October 15, 2025).*

PUBLIC FLOAT AND FREE FLOAT

Immediately following completion of the Global Offering and based on the Offer Price of HK\$11.60 per H Share:

- (1) 134,585,396 H Shares (without taking into account of the Reserved Shares) representing approximately 25.98% of the total number of issued Shares of our Company will be counted towards the public float for the purpose of Rule 19A.13A of the Listing Rules, which is higher than the prescribed percentage of H Shares required to be held in public hands of approximately 24.96% under Rule 19A.13A of the Listing Rules; and
- (2) the Company satisfies the free float requirement pursuant to Rule 19A.13C(1) of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders do not hold more than 50% of the Shares held in the public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday, October 15, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the paragraphs headed “Underwriting – Underwriting Arrangements and Expenses – The Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Wednesday, October 15, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Wednesday, October 15, 2025 (Hong Kong time).

The H Shares will be traded in board lots of 500 H Shares each, and the stock code of the H Shares will be 2575.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun

Chairperson of the Board and executive Director

Hong Kong, October 14, 2025

As of the date of this announcement, the board of directors of the Company comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.